Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Area of Science:

• Oncology
• Urology

Background:

• Renal cell carcinoma (RCC) management for relapsed or stage IV disease involves surgery and systemic therapy.
• Tumor histology and patient risk stratification are crucial for selecting appropriate treatments.

Purpose of the Study:

• To summarize the National Comprehensive Cancer Network (NCCN) Guidelines for Kidney Cancer regarding surgical and systemic therapy for advanced RCC.
• To outline the NCCN Kidney Cancer Panel's categorization of systemic therapy regimens.

Main Methods:

• Review of the NCCN Guidelines for Kidney Cancer.
• Stratification of treatment recommendations by RCC histology and patient risk groups.
• Categorization of systemic therapies into 'Preferred,' 'Other Recommended Regimens,' and 'Useful in Certain Circumstances.'

Main Results:

• Treatment recommendations for advanced RCC are stratified by histology and risk.
• Systemic therapies are categorized to guide clinical decision-making.
• Factors influencing treatment selection include efficacy, safety, evidence, comorbidities, disease characteristics, and access to agents.

Conclusions:

• The NCCN Guidelines provide a structured approach to managing relapsed or stage IV RCC.
• Categorization of systemic therapies aids clinicians in selecting optimal treatment regimens.
• Personalized treatment selection for advanced RCC integrates clinical and patient-specific factors.